Searchable abstracts of presentations at key conferences in endocrinology

ea0094p40 | Bone and Calcium | SFEBES2023

Importance of Evidence-based management of Primary Hyperparathyroidism

Ahmed Nabeel , Hatton Rebecca , Harris Laura , Tabasum Maria , Clarke-Burns Rossana , Brotherton Sophie , Srinivasshankar Upendram

Background: Primary Hyperparathyroidism (PHPT) is the leading cause of hypercalcaemia. Early diagnosis and management is important to prevent long term complications. National institute of clinical excellence (NICE) published guidelines on diagnosis and management of Primary Hyperparathyroidism and we sought to compare our practice with the NICE guideline (NG 132).Methods: This was a retrospective observational study of ...

ea0094p244 | Neuroendocrinology and Pituitary | SFEBES2023

Co-occurrence of neurofibromatosis type 1 and pituitary rathke cleft cyst

Tabasum Maria , Ahmed Nabeel , Harris Laura , Clarke-Burns Rosanna , Brotherton Sophie , Srinivas-Shankar Upendram

Introduction: The most common sellar and suprasellar lesions are pituitary adenomas, craniopharyngiomas and benign cysts. Rathke’s cleft cyst (RCC) is a benign developmental sellar or suprasellar cystic lesion, which is rarely symptomatic.Case HistoryWe present the case history of 21-year-old woman with a suprasellar RCC, causing early optic chiasmal compression and associated with hyperprolactinemia. Past medical history included neurofibromatosis type 1...

ea00100we5.1 | Workshop E: Disorders of the gonads | SFEEU2024

What is optimal sex steroid replacement and treatment of osteoporosis in turner syndrome?

Taylor Sophie , Parsons Laura , Tabasum Maria , Gleeson Julia , Harris Laura , Srinivas-Shankar Upendram

Background: Turner syndrome (TS) affects around 1:2000 women and is the most common genetic cause of primary ovarian failure (POF). These patients require timely sex steroid replacement and are at increased risk of osteoporosis.Clinical case: A 34-year-old female diagnosed with TS aged 10 years, attended the endocrine clinic after her care was transferred from Ukraine. She received growth hormone treatment for 4 years from the age of 12 and was commenced...

ea0081p608 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Dysregulation of cytochrome P450 oxidoreductase (POR) in NAFLD and hepatocellular carcinoma; evidence from clinical, rodent and cellular models

da Conceicao Ismael , Nikolaou Nikolaos , Gathercole Laura , Harris Shelley , Dempster Niall , Moolla Ahmad , Hodson Leanne , Tomlinson Jeremy

The incidence of non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of the metabolic syndrome, continues to rise. NAFLD is associated with significant liver-specific and cardiovascular morbidity and mortality, including hepatocellular carcinoma (HCC). Currently, there are no licensed therapies, highlighting the importance of understanding the pathogenic mechanisms that drive the condition. Cytochrome p450 oxidoreductase (POR) plays an essential role in activa...